© 2017 Pharmstandard Ventures
BioNTech
Mainz, Germany
Year of Investment: 2016
IPO in June, 2018
BioNTech
Mainz, Germany
Year of Investment: 2016
IPO in June, 2018
Merger transaction between Neon Therapeutics and BioNTech in May, 2020
Merger transaction between Neon Therapeutics and BioNTech in May, 2020
Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma, and Pfizer
For more information, please visit:
https://biontech.de/
For more information, please visit:
https://biontech.de/
Pharmstandard Ventures is looking for innovative drug discovery/development projects targeting the unmet medical needs or providing dramatic advantages over the competition globally